BACKGROUND: False-positive cancer screening results may affect a patient's willingness to obtain future screening. METHODS: The authors conducted logistic regression analysis of 450,484 person-years of electronic medical records (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) 
INTRODUCTION
False-positive cancer screening test results are common. Over 10 years, approximately 50% to 61% of women undergoing annual mammography and 10% to 12% of men undergoing regular prostate-specific antigen (PSA) testing will experience a false-positive result. [1] [2] [3] [4] Similarly, approximately 23% of individuals undergoing regular fecal occult blood tests (FOBTs) will experience a positive result with negative follow-up colonoscopy. 5 Efforts to reduce false-positive results are cited in support of biennial (vs annual) mammography, 6 whereas overdiagnosis, which might be considered a false-positive result because patients are treated unnecessarily, is cited in recommendations against routine prostate cancer screening as well as screening for breast and colorectal cancers for some populations. [6] [7] [8] [9] False-positive cancer screening test results may affect an individual's willingness to continue screening for cancer in the future; approximately 40% of women experiencing a false-positive mammogram labeled the experience as "very scary" or the "scariest time of my life." 10 However, implications are unclear. Individuals may believe they "almost had cancer" and become more interested in future screening. This hypothesis is supported by surveys suggesting that women consider false-positive results an acceptable consequence of mammography, 11 with nearly all women reporting satisfaction with the initial screening test. 10 Retrospective work suggests that women with false-positive mammography results were more likely to return for subsequent screening. 12 Alternatively, individuals may recognize false-positive test results as a harm and become less interested in future screening. Some studies have found lower screening reattendance rates after false-positive mammography findings, 6, 13, 14 including recent work, 15 but to our knowledge the reasons are unclear. 6 Consequences may vary by population; a meta-analysis demonstrated 7% higher odds of future screening for US women after falsepositive mammography, but 37% lower odds in Canadian women. 16 Lower reattendance also was found in Europe after false-positive mammography results, [17] [18] [19] particularly among women who underwent biopsy. 18 Finally, false-positive findings may have no impact. 20, 21 To the best of our knowledge, little is known regarding the implications of false-positive test results for patients with colorectal and prostate cancers.
Historically, investigation of this issue has been limited by available data. Prospective studies are difficult because of the need for long-term follow-up data. Medicare administrative claims are not ideal because many individuals experience a false-positive test result before age 65 years. [1] [2] [3] [4] [5] Commercial insurer data are limited by an average enrollment of <3 years per patient. 22 Administrative data also lack important clinical information, such as family history, obesity, and tobacco use, which may influence cancer risk and screening decisions.
In the current study, we used 10 years of electronic medical record (EMR) data to analyze the association between prior receipt of a false-positive cancer screening test result and future participation in routine cancer screenings, adjusted for a wide variety of patient risk factors and demographics.
MATERIALS AND METHODS

Data and Patients
We used EMR data from 2006 through 2015 for the Cleveland Clinic health care system. The system has 1 large academic medical center, 13 regional hospitals, 21 family health centers, and >75 outpatient locations. We considered encounters, diagnoses (on at least 2 encounters 30 days apart), 23 completed procedures, surgeries, prescriptions, preventive health maintenance, smoking status, family history, demographics, and address history (free text notes were not considered). Because we only had information regarding care received within the system, we identified patients who received continuing primary care and therefore were more likely to have complete cancer screening data. Specifically, we required Ohio residence, 5 years of EMR data, and visits to an internal medicine or family medicine provider in 3 different years. For example, if a patient had primary care visits in each year of 2009 through 2012 and 2014, then the patient was included from 2009 through 2014 (but not earlier or later years). Results were robust to variations in these requirements. For each patient, we used data for the first 2 years to establish cancer screening history (eg, annual vs biennial mammography and receipt of false-positive test results) and data from the remaining years for analyses. Patients were aged 50 to 75 years and had no known history of cancer (other than nonmelanoma skin cancer) or bilateral mastectomy.
Cancer Screening Experiences
False-positive test results
Patients were considered to have undergone a falsepositive cancer screening test if they received a result that might raise concern but did not result in a cancer diagnosis. Specifically, patients with a positive FOBT and negative follow-up colonoscopy within 6 months, without biopsy or polypectomy, were considered to have experienced false-positive colorectal cancer screening; we did not consider false-positive results for patients who underwent initial colonoscopy because repeat screening would not be expected during the study period. Women with repeat breast imaging (mammogram, ultrasound, magnetic resonance imaging) or negative breast biopsy 3 months after screening mammography were considered to have experienced false-positive breast cancer screening. Finally, men without a history of benign prostate hyperplasia, lower urinary tract symptoms, or prostatitis who had a PSA test result 4.0 ng/mL and a repeat PSA test within 3 months, or any PSA test result with negative follow-up prostate biopsy within 3 months, were considered to have experienced false-positive prostate cancer screening. We reasoned that, even when prostate cancer screening was not recommended, men who had obtained it and experienced a false-positive finding might change their willingness to undergo guideline-recommended colorectal cancer screening. The majority of cancer screenings were ordered by request, but periodic organized initiatives (eg, mailings) informed some patients of screening eligibility and invited them to schedule appointments. For mammography, medical assistants often facilitated screening before a physician entered the room. Diagnostic cancer testing (indicated by procedure names [eg, "occult blood diagnostic"]) was not considered.
Up-to-date status
At the end of each year, we determined up-to-date status for each patient with US Preventive Services Task Forcerecommended cancer screenings (patients without visits were considered not to have received screening in that year, but could be up to date based on previous years). Patients were considered to be up to date with colorectal cancer screening after receipt of FOBT within 1 year, flexible sigmoidoscopy within 5 years (with or without midinterval FOBT), or colonoscopy within 10 years. Women were considered up to date with breast cancer screening after receipt of mammography or breast magnetic resonance imaging within 2 years (1 year in sensitivity analyses). Up-to-date status with prostate cancer screening was not included because guidelines occasionally recommended against routine screening 4, [24] [25] [26] [27] ; however, receipt of prostate cancer screening within the past 2 years was addressed as supplementary analysis.
Covariates
For each person-year, we identified cardiovascular risk factors (smoking status, body mass index, blood pressure, lipids, and hemoglobin A1c), comorbidity (Charlson score of 0 vs 1), 23 family history of colorectal or breast cancer (first-degree relative, second-degree relative, male breast cancer, or unknown), receipt of influenza vaccination, demographics (age, race, ethnicity, marital status, health insurance type, census block group median income by race), primary care site and physician specialty (internal medicine, family medicine), primary care use (number of visits within previous 365 days), employee/dependent of the health system, and year. For colorectal cancer screening, we also included current anticoagulation prescriptions (yes/no) and diagnosis of familial adenomatous polyposis/hereditary nonpolyposis colon cancer, Crohn colitis, and ulcerative colitis. For breast cancer screening, we also included current postmenopausal hormone replacement therapy prescriptions (yes/no) and each woman's breast cancer screening frequency (based on the mode of historic data as annual, biennial, and less than biennial). In sensitivity analyses, breast cancer screening frequency was redefined as the average number of breast cancer screenings per year of historic data (0.5 vs >0.5) and the total number of breast cancer screenings in historic data (0, 1, 2, and 3; maximum of 1/year). For these analyses, "historic" was defined as the first available year of EMR data for the patient since her 50th birthday (or earlier, if known receipt of breast cancer screening) through the current year under consideration.
Statistical Analyses
We used logistic regression models to analyze the association between cancer screening experiences and up-to-date status with colorectal cancer screening (stratified by sex) or breast cancer screening (3 separate outcomes; 1 per cancer type/sex). For colorectal cancer screening, we included prior breast and prostate cancer false-positive results, but excluded colorectal cancer false-positive findings because for most individuals, we only expected 1 colonoscopy to be performed during the study period. For breast cancer screening, we included prior breast and colorectal cancer false-positive results. We examined both unadjusted models (which only considered the independent variable of interest, namely prior receipt of a false-positive cancer screening) and models adjusted for covariates. An adjusted odds ratio (AOR) >1 would suggest that individuals with prior false-positive results were more likely to undergo future cancer screenings. We expected to find AORs >1 across cancer types, indicating that individuals increased the intensity of their screening practices after a falsepositive finding. In alternate models, we considered the number of prior false-positive results from breast and prostate cancer screenings (0, 1, or 2) (multiple falsepositive results from colorectal cancer screening would not be expected) and fixed effects for each physician with 100 patients who underwent screening each year. As a secondary outcome, we considered the association between up-to-date status with colorectal or breast cancer screening and receipt of other cancer screening (regardless of screening test outcome).
To consider the possibility that EMRs may have been incomplete in early years, we also conducted analyses that eliminated data from 2006 through 2008. Finally, in 2 separate models, we tested the association between prior receipt of a false-positive cancer screening and diagnosis with hyperlipidemia or diabetes, outcomes that should be unrelated to cancer screening status (expected AOR, 1) but were considered because both cancer screening and lipids/diabetes diagnoses (which require patients to obtain a blood test) may act as a proxy for health care system engagement.
Standard errors were clustered by individual. Significance tests were 2-sided at the 5% level. This study was approved by the Cleveland Clinic institutional review board.
RESULTS
We identified 92,405 patients aged 50 to 75 years across 450,484 person-years. Tables 1 and 2 show summary statistics. Among at-risk individuals, 62% and 85%, respectively, were up to date with colorectal and breast cancer screenings. Approximately 29% of at-risk individuals had a prior breast cancer false-positive result, 3% had a prior prostate cancer false-positive result, and 2% had a prior colorectal cancer false-positive result.
In both unadjusted and adjusted models, a prior false-positive breast or prostate cancer test result was strongly associated with being up to date with cancer screenings ( False-positive results were not considered for patients who underwent initial colonoscopy because repeat screening would not be expected during the study period. A greater number of prior breast or prostate cancer false-positive results was associated with a trend toward being up to date with screening (Table 4) . Women who had 1 and 2 false-positive breast cancer screening results had 16% and 50% higher odds, respectively, of being up to date with colorectal cancer screening compared with women with no false-positive results (AOR, 1.16 [95% CI, 1.10-1.23] and AOR, 1.50 [95% CI, 1.35-1.67], respectively; P for trend <.001) (column 1). The same women had 34% and 163% higher odds, respectively, of being up to date with breast cancer screening compared with women with no false-positive results (P for trend <.001) (column 2). Similarly, men with 1 and 2 falsepositive prostate cancer screening results had 18% and 40% higher odds, respectively, of being up to date with colorectal cancer screening (P for trend 5.005) (column 3). In supplemental analysis, men who previously had a colorectal cancer FOBT false-positive result were more likely to have received prostate cancer screening within the past 2 years (P<.001).
Individuals who received 1 cancer screening were more likely to obtain other screenings (Table 3) . Women who were up to date with breast cancer screening were more likely to be up to date with colorectal cancer screening (AOR, 1.78 [95% CI, 1.68-1.90; P<.001]) (column 2) and, similarly, women who were up to date with colorectal cancer screening were more likely to be up to date with breast cancer screening (AOR, 1.81 [95% CI, 1.69-1.93; P<.001]) (column 4). Men who had received prostate cancer screening within the prior 2 years were more likely to be up to date with colorectal cancer screening (AOR, 1.34 [95% CI, 1.27-1.42; P<.001]) (column 6).
Results were robust to definition of breast cancer screening history, controls for each physician, and the exclusion of data from 2006 through 2008. As expected, AORs for alternate outcomes of diagnosis with hyperlipidemia or diabetes were not significantly different from 1.
DISCUSSION
In the current study examining EMRs for >90,000 individuals followed over approximately 7 years, past experiences with cancer screening were found to be positively associated with receipt of future cancer screenings. In general, those who were up to date with 1 cancer screening were more likely to obtain other screenings, an intuitive finding noted by others. [28] [29] [30] More interestingly, individuals who had experienced a prior false-positive breast or prostate cancer screening test result were much more likely to participate in future screenings compared with individuals who had not experienced a false-positive result. This is consistent with prior survey and psychosocial research suggesting that women who experience falsepositive mammogram results feel relief at not having cancer, 10, 11, 16 but contrasts with recent retrospective work indicating lower mammography rates after false-positive breast cancer screenings. 15 In addition, in our analysis, not all false-positive results had the same effect; false- Abbreviations: 95% CI, 95% confidence interval; AOR, adjusted odds ratio. a The number of false-positive fecal occult blood test results was not assessed because average-risk patients with 1 false-positive result and a negative follow-up colonoscopy would not be expected to be rescreened during the sample period. Adjusted for covariates as described in the article.
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Cancer June 1, 2018 positive mammogram findings requiring biopsy had the strongest impact, whereas women with a prior falsepositive colorectal cancer FOBT screening result had lower odds of being up to date with breast cancer screening.
It is desirable for individuals to obtain guidelinerecommended screening, and therefore if false-positive results increase the probability of adherence, they might be construed as having beneficial aspects. This interpretation would depend on reasons for increased adherence. There are at least 3 possibilities. False-positive results may simply be salient reminders to screen for cancer, 31 without detriment to the individual's quality of life. Second, falsepositive results may prompt an increase in an individual's perceived likelihood of developing cancer and consequently raise screening interest. 32 Because studies have suggested that the majority of individuals overestimate their cancer risk 33 and screening benefits, 34 from this perspective, false-positive results may be harmful. Finally, if improved adherence is due to increased anxiety or vulnerability regarding having cancer, then false-positive results may impose long-lasting negative consequences. 35 This viewpoint follows 5 systematic reviews, 6, 16, [36] [37] [38] including a 2016 study accompanying the recent US Preventive Services Task Force breast cancer screening recommendation, 6 that found mostly temporary psychological responses in women with false-positive mammogram results. The current study findings, if consistent with this theory, would suggest persistent anxiety. Nevertheless, nearly all systematic review findings were limited by small sample size, narrowly selected participants, a lack of clinical information, and limited follow-up. 6 Although the results of the current study suggest a strong association between prior receipt of a breast or prostate cancer falsepositive result and future participation in cancer screenings, we cannot discern the reason. Additional research is needed to understand the impact of false-positive testing results and potential ways to ameliorate it.
Similarly, research is needed to understand why false-positive colorectal cancer FOBT screening results may lead to decreased breast cancer screening adherence. One possible explanation is that women who chose FOBT (instead of colonoscopy) initially were more hesitant to undergo screening, and a false-positive result reinforced that belief. If this explanation is correct, then results may vary by sex; an exploratory analysis found that men with false-positive colorectal cancer FOBT screening findings had 15% higher odds of undergoing prostate cancer screening.
Limitations
The results of the current study may be confounded by past screening history; individuals with more cancer screenings are more likely both to experience falsepositive results and to engage in future screening. However, we included breast cancer screening history as a covariate, and the results were robust to various definitions of that term. Second, we had no information regarding health care received outside of a single system. However, we limited our analysis to patients with ongoing primary care, in whom cancer screening often takes place. Third, EMR data may have been incomplete for some variables (eg, family history) or in early years, although sensitivity analyses excluding data for 2006 through 2008 yielded similar results. We had no information concerning education, attitudes toward screening, screening barriers, or out-of-pocket costs. Fourth, only 1.3% of patients were insured by Medicaid, thereby limiting generalizability to low-income populations. Fifth, previous breast biopsy is a risk factor for future breast cancer diagnosis, 39 suggesting a valid reason for higher future screening rates in some women. A more common situation, repeat breast imaging without biopsy, also may be associated with future breast cancer, 40 although this association has been described only recently and is unlikely to explain the results of the current study. Sixth, the majority of cancer screenings were ordered during routine clinical care, and therefore results may not extend to organized cancer screening programs. Individuals with false-positive results may have been reminded about the need for cancer screenings during follow-up testing. Finally, the observational design of the current study allowed us to identify associations, not causality.
Conclusions
Prior experience with cancer screenings may influence a patient's willingness to continue future screening. Patients who previously experienced a false-positive breast or prostate cancer screening result were more likely to engage in future screening for all cancers, whereas women with a false-positive colorectal cancer FOBT screening result were less likely to engage in future breast cancer screening. Future research should seek to confirm the current study results, explore reasons for the possible long-lasting influence of false-positive findings, consider whether providers should be alerted to monitor cancer screening after a falsepositive result (eg, mammography after a false-positive FOBT), and address ways for health care providers to minimize negative impact on patients.
